Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
UNITY Biotechnology (NASDAQ:UBX) stock fell 30% after the company's mid-stage trial for its diabetic macular edema treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback